Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.74 |
| ▸ | ACACB | O00763 | 1/20 | 0.71 |
| ▸ | ACACA | Q13085 | 1/20 | 0.71 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | CPT2 | P23786 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190226 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL6254902 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL20474799 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL1832600 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL1836313 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL5528331 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL9177458 | 1.00 | ACLY (0.74) | ACLYACACBACACATBXAS1TDP1 | |
| Ammonia Solution, Strong SCHEMBL9181436 | 0.97 | ACLY (0.71) | ACLYACACBACACATBXAS1TDP1 | |
| SCHEMBL7222208 | 0.97 | ACLY (0.70) | ACLYACACBACACATBXAS1TDP1 | |
| Ammonia Solution, Strong SCHEMBL9177435 | 0.94 | ACLY (0.67) | ACLYACACBACACATBXAS1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | claimed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | claimed |
| US-9375519-B2 | Bioerodable poly(etheresteramides) and medical article uses | SURMODICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| WO-2014004512-A1 | BIOERODABLE POLY(ETHERESTERAMIDES) AND MEDICAL ARTICLE USES | SURMODICS, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20130344126-A1 | BIOERODABLE POLY(ETHERESTERAMIDES) AND MEDICAL ARTICLE USES | BANK OF MONTREAL, AS COLLATERAL AGENT | 2013-12-26 | — | — | US | disclosed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1651205-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | Warner-Lambert Company LLC (US) | 2006-05-03 | — | — | EP | disclosed |
| CN-1678297-A | Method of treating osteoarthritis | WARNER LAMBERT CO (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1572189-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1539127-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005009431-A1 | METHODS FOR TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISEASES WITH A STATIN AND ETHER | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005002557-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ETHER AND SELECTIVE COX-2 INHIBITOR AND USES THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004045596-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| US-6570028-B1 | Reacting a diacid with epi(chloro or bromo)hydrin; using Group 1a hydroxide catalyst; distillation | RESOLUTION PERFORMANCE PRODUCTS LLC | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | ACLY 3034/4885ACACB 2221/4885ACACA 1120/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | ACLY 560/4885ACACB 412/4885ACACA 228/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | ACLY 1581/4885ACACB 608/4885ACACA 718/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | ACLY 1982/4885ACACB 1067/4885ACACA 1964/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | ACLY 2661/4885ACACB 1828/4885ACACA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.